Sangamo Shares Plummet After Pfizer Exit
Sangamo Therapeutics shares plunged 50% as Pfizer ends collaboration on hemophilia drug, impacting biotech stocks. Discover the implications for investors.
Topic
biotech stocks
A collection of 3 issues
Sangamo Stock Falls as Pfizer Ends Hemophilia Collaboration
Sangamo Therapeutics' stock dropped sharply after Pfizer announced it is ending their collaboration on a groundbreaking hemophilia drug. Discover the impact on biotech stocks.
Sangamo Stock Drops 67% After Pfizer Partnership Ends
Sangamo Therapeutics' shares nosedived by 67% following Pfizer's decision to terminate their hemophilia A gene therapy collaboration. Explore the impact on biotech stocks.